Interestingly, our results in both, the experimental and validation cohorts suggest a tumor-suppressive role of RUNX1 in HGSOCs, but only in the subgroup without missense mutations in TP53, where its elevated expression correlated with the decreased risk of tumor recurrence. Here, RUNX1 is linked to neoplasm.